Cargando…

Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study

BACKGROUND: Nonmotor symptoms (NMS) are common in advanced Parkinson's disease (APD) and reduce health-related quality of life. OBJECTIVE: The aim of the study was to evaluate levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment (OMT) on NMS in APD. METHODS: INSIGHTS was...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Sun Ju, Calopa, Matilde, Ceravolo, Maria G., Tambasco, Nicola, Antonini, Angelo, Chaudhuri, K. Ray, Robieson, Weining Z., Sánchez-Soliño, Olga, Zadikoff, Cindy, Jin, Man, Barbato, Luigi M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652073/
https://www.ncbi.nlm.nih.gov/pubmed/36388237
http://dx.doi.org/10.1155/2022/1216975
_version_ 1784828386276802560
author Chung, Sun Ju
Calopa, Matilde
Ceravolo, Maria G.
Tambasco, Nicola
Antonini, Angelo
Chaudhuri, K. Ray
Robieson, Weining Z.
Sánchez-Soliño, Olga
Zadikoff, Cindy
Jin, Man
Barbato, Luigi M.
author_facet Chung, Sun Ju
Calopa, Matilde
Ceravolo, Maria G.
Tambasco, Nicola
Antonini, Angelo
Chaudhuri, K. Ray
Robieson, Weining Z.
Sánchez-Soliño, Olga
Zadikoff, Cindy
Jin, Man
Barbato, Luigi M.
author_sort Chung, Sun Ju
collection PubMed
description BACKGROUND: Nonmotor symptoms (NMS) are common in advanced Parkinson's disease (APD) and reduce health-related quality of life. OBJECTIVE: The aim of the study was to evaluate levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment (OMT) on NMS in APD. METHODS: INSIGHTS was a phase 3b, open-label, randomized, multicenter study in patients with APD (LCIG or OMT, 26 weeks) (NCT02549092). Primary outcomes assessed were total NMS (NMS scale (NMSS) and PD sleep scale (PDSS-2)). Key secondary outcomes included the Unified PD Rating Scale (UPDRS) Part II, Clinical Global Impression of Change (CGI-C), and PD Questionnaire-8 (PDQ-8). Additional secondary measures of Patient Global Impression of Change (PGIC), King's PD Pain Scale (KPPS), and Parkinson Anxiety Scale (PAS) also were evaluated. Finally, safety was assessed. RESULTS: Out of 89 patients randomized, 87 were included in the analysis (LCIG, n = 43; OMT, n = 44). There were no significant differences in NMSS or PDSS-2 total score changes (baseline to Week 26) between LCIG and OMT; within-group changes were significant for NMSS (LCIG, p < 0.001; OMT, p = 0.005) and PDSS-2 (LCIG, p < 0.001; OMT, p < 0.001). Between-group treatment differences were nominally significant for UPDRS Part II (p = 0.006) and CGI-C (p < 0.001) at Week 26 in favor of LCIG; however, statistical significance could not be claimed in light of primary efficacy outcomes. PGIC (Week 26) and KPPS (Week 12) scores were nominally significantly reduced with LCIG versus OMT (p < 0.001; p < 0.05). There were no significant differences in PDQ-8 or PAS. Adverse events (AEs) were mostly mild to moderate; common serious AEs were pneumoperitoneum (n = 2) and stoma-site infection (n = 2) (LCIG). CONCLUSIONS: There were no significant differences between LCIG versus OMT in NMSS or PDSS-2; both LCIG and OMT groups significantly improved from baseline. AEs were consistent with the known safety profile.
format Online
Article
Text
id pubmed-9652073
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-96520732022-11-15 Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study Chung, Sun Ju Calopa, Matilde Ceravolo, Maria G. Tambasco, Nicola Antonini, Angelo Chaudhuri, K. Ray Robieson, Weining Z. Sánchez-Soliño, Olga Zadikoff, Cindy Jin, Man Barbato, Luigi M. Parkinsons Dis Research Article BACKGROUND: Nonmotor symptoms (NMS) are common in advanced Parkinson's disease (APD) and reduce health-related quality of life. OBJECTIVE: The aim of the study was to evaluate levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment (OMT) on NMS in APD. METHODS: INSIGHTS was a phase 3b, open-label, randomized, multicenter study in patients with APD (LCIG or OMT, 26 weeks) (NCT02549092). Primary outcomes assessed were total NMS (NMS scale (NMSS) and PD sleep scale (PDSS-2)). Key secondary outcomes included the Unified PD Rating Scale (UPDRS) Part II, Clinical Global Impression of Change (CGI-C), and PD Questionnaire-8 (PDQ-8). Additional secondary measures of Patient Global Impression of Change (PGIC), King's PD Pain Scale (KPPS), and Parkinson Anxiety Scale (PAS) also were evaluated. Finally, safety was assessed. RESULTS: Out of 89 patients randomized, 87 were included in the analysis (LCIG, n = 43; OMT, n = 44). There were no significant differences in NMSS or PDSS-2 total score changes (baseline to Week 26) between LCIG and OMT; within-group changes were significant for NMSS (LCIG, p < 0.001; OMT, p = 0.005) and PDSS-2 (LCIG, p < 0.001; OMT, p < 0.001). Between-group treatment differences were nominally significant for UPDRS Part II (p = 0.006) and CGI-C (p < 0.001) at Week 26 in favor of LCIG; however, statistical significance could not be claimed in light of primary efficacy outcomes. PGIC (Week 26) and KPPS (Week 12) scores were nominally significantly reduced with LCIG versus OMT (p < 0.001; p < 0.05). There were no significant differences in PDQ-8 or PAS. Adverse events (AEs) were mostly mild to moderate; common serious AEs were pneumoperitoneum (n = 2) and stoma-site infection (n = 2) (LCIG). CONCLUSIONS: There were no significant differences between LCIG versus OMT in NMSS or PDSS-2; both LCIG and OMT groups significantly improved from baseline. AEs were consistent with the known safety profile. Hindawi 2022-11-04 /pmc/articles/PMC9652073/ /pubmed/36388237 http://dx.doi.org/10.1155/2022/1216975 Text en Copyright © 2022 Sun Ju Chung et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chung, Sun Ju
Calopa, Matilde
Ceravolo, Maria G.
Tambasco, Nicola
Antonini, Angelo
Chaudhuri, K. Ray
Robieson, Weining Z.
Sánchez-Soliño, Olga
Zadikoff, Cindy
Jin, Man
Barbato, Luigi M.
Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study
title Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study
title_full Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study
title_fullStr Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study
title_full_unstemmed Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study
title_short Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study
title_sort effects of levodopa-carbidopa intestinal gel compared with optimized medical treatment on nonmotor symptoms in advanced parkinson's disease: insights study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652073/
https://www.ncbi.nlm.nih.gov/pubmed/36388237
http://dx.doi.org/10.1155/2022/1216975
work_keys_str_mv AT chungsunju effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy
AT calopamatilde effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy
AT ceravolomariag effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy
AT tambasconicola effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy
AT antoniniangelo effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy
AT chaudhurikray effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy
AT robiesonweiningz effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy
AT sanchezsolinoolga effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy
AT zadikoffcindy effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy
AT jinman effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy
AT barbatoluigim effectsoflevodopacarbidopaintestinalgelcomparedwithoptimizedmedicaltreatmentonnonmotorsymptomsinadvancedparkinsonsdiseaseinsightsstudy